# Janssen R&D Ireland clinical trials: 32 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials with Janssen R&D Ireland as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen R&D Ireland: 32 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-r-and-d-ireland

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 25, 2015 | NCT02397395 | An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With... | Janssen R&D Ireland | Phase 2 | Withdrawn | Renal Impairment, End-stage Renal Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02397395) |
| October 21, 2014 | NCT02269917 | Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted... | Janssen R&D Ireland | Phase 3 | Completed | Human Immunodeficiency Virus Type 1 | 1,149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02269917) |
| September 26, 2014 | NCT02250807 | Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection | Janssen R&D Ireland | Phase 3 | Completed | Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02250807) |
| May 7, 2014 | NCT02132923 | A Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Infections | Janssen R&D Ireland | Observational | Completed | Respiratory Syncytial Virus | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02132923) |
| February 17, 2014 | NCT02064842 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the... | Janssen R&D Ireland | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02064842) |
| December 23, 2013 | NCT02018536 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in... | Janssen R&D Ireland | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02018536) |
| September 10, 2013 | NCT01938625 | A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and... | Janssen R&D Ireland | Phase 2 | Completed | Hepatitis C, Chronic | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01938625) |
| November 14, 2012 | NCT01725529 | An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients | Janssen R&D Ireland | Phase 3 | Completed | Hepatitis C, Chronic | 457 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01725529) |
| November 9, 2012 | NCT01724086 | A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without... | Janssen R&D Ireland | Phase 2 | Completed | Chronic Hepatitis C | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01724086) |
| November 1, 2012 | NCT01719614 | A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants | Janssen R&D Ireland | Phase 1 | Completed | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01719614) |
| October 16, 2012 | NCT01707342 | A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and... | Janssen R&D Ireland | Phase 1 | Completed | Healthy Male Participants | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01707342) |
| August 10, 2012 | NCT01662661 | A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants | Janssen R&D Ireland | Phase 1 | Completed | Healthy Participants | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01662661) |
| July 27, 2012 | NCT01651767 | Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382 | Janssen R&D Ireland | Phase 1 | Terminated | Chronic Hepatitis C Infection | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01651767) |
| June 14, 2012 | NCT01619527 | A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions | Janssen R&D Ireland | Phase 1 | Completed | Healthy Participants | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01619527) |
| June 8, 2012 | NCT01615614 | A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants | Janssen R&D Ireland | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01615614) |
| April 26, 2012 | NCT01586325 | A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian... | Janssen R&D Ireland | Phase 1 | Terminated | Chronic Hepatitis C Infection | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01586325) |
| April 20, 2012 | NCT01582035 | Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir | Janssen R&D Ireland | Phase 1 | Completed | Hepatitis C | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01582035) |
| April 5, 2012 | NCT01571570 | A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435. | Janssen R&D Ireland | Phase 1 | Completed | Healthy Volunteers | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01571570) |
| March 30, 2012 | NCT01567735 | A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in... | Janssen R&D Ireland | Phase 3 | Completed | Hepatitis C | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01567735) |
| January 26, 2012 | NCT01519128 | A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin | Janssen R&D Ireland | Phase 1 | Completed | Healthy | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01519128) |
| December 6, 2011 | NCT01485991 | TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic... | Janssen R&D Ireland | Phase 3 | Completed | Hepatitis C | 771 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01485991) |
| November 30, 2011 | NCT01482611 | A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 | Janssen R&D Ireland | Phase 1 | Completed | Hepatitis C Virus Infection | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01482611) |
| November 28, 2011 | NCT01479868 | A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin... | Janssen R&D Ireland | Phase 3 | Completed | Hepatitis C Virus Genotype-1 | 109 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01479868) |
| November 8, 2011 | NCT01466790 | A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To... | Janssen R&D Ireland | Phase 2 | Completed | Hepatitis C | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01466790) |
| August 23, 2011 | NCT01422330 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral... | Janssen R&D Ireland | Phase 4 | Completed | Human Immunodeficiency Virus (HIV) Infection | 211 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01422330) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 2 | 5 |
| Phase 3 | 12 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 29 |
| Terminated | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis C | 12 |
| Acquired Immunodeficiency Syndrome | 6 |
| Hepatitis C, Chronic | 4 |
| Hepatitis | 1 |
| Liver Diseases | 1 |
| Virus Diseases | 1 |
| Renal Insufficiency | 1 |
| Kidney Failure, Chronic | 1 |
| HIV Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [Bar and grill restaurants in the United States](https://specstream.ai/data/businesses/bar-and-grill-restaurants/united-states)
- [Vegetarian restaurants in the United States](https://specstream.ai/data/businesses/vegetarian-restaurants/united-states)
- [Real estate firms in the United States](https://specstream.ai/data/businesses/real-estate-firms/united-states)
- [Mental health clinics in the United States](https://specstream.ai/data/businesses/mental-health-clinics/united-states)
- [Gutter contractors in the United States](https://specstream.ai/data/businesses/gutter-contractors/united-states)
